About
Small Molecules, Biologics
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalSoutheastern U.S.
Clinical Trials (15)
View allTotal Trials
15
As Lead Sponsor
9
As Collaborator
6
Total Enrollment
669
By Phase
PHASE2: 7PHASE1/PHASE2: 5EARLY_PHASE1: 1PHASE3: 1
By Status
COMPLETED: 5TERMINATED: 5ACTIVE_NOT_RECRUITING: 2SUSPENDED: 1RECRUITING: 1AVAILABLE: 1
Clinical Trials Pipeline14 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT05494697Lead Sponsor
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
PHASE2Suspended
90 participants
Started: Jun 30, 2026 · Completed: Jan 31, 2030
NCT05927142Collaborator
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
PHASE1/PHASE2Recruiting
43 participants
Started: Jan 9, 2024 · Completed: Apr 30, 2027
NCT05592418Lead Sponsor
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
PHASE2Completed
80 participants
Started: Jun 30, 2023 · Completed: Nov 30, 2023
NCT03899987Collaborator
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
PHASE2Active, not recruiting
12 participants
Started: Nov 29, 2019 · Completed: Nov 29, 2026
NCT03734692Collaborator
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
PHASE1/PHASE2Active, not recruiting
24 participants
Started: Jan 28, 2019 · Completed: Jan 10, 2027
Locations (1)
Headquarters
Ocala, FL, United States
Map
Loading map...